The withdrawal of rofecoxib.
Arellano
Félix M
FM
Risk Management Resources, Califon, NJ 07830, USA. arellanofm@msn.com
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000517:prevention & control; D002986:Clinical Trials as Topic; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D016757:Death, Sudden, Cardiac / Q000209:etiology; D004345:Drug Industry / Q000191:economics; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000627:therapeutic use; D009288:Naproxen / Q000627:therapeutic use; D017891:Pharmacoepidemiology / Q000379:methods / Q000706:statistics & numerical data; D011358:Product Surveillance, Postmarketing / Q000379:methods* / Q000592:standards / Q000706:statistics & numerical data; D013450:Sulfones / Q000009:adverse effects* / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib; D009288:Naproxen; D001241:Aspirin